Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 1, pp 21–31 | Cite as

A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort

  • Chiranjit MaityEmail author
  • Anil Kumar Gupta
Clinical Trial
  • 129 Downloads

Abstract

Purpose

Increasing resistance towards antibiotics has augmented the use of probiotics for the treatment of diarrhea and associated symptoms. Probiotics are active microorganisms which exert some health benefits when consumed in the right amount. This randomized, double-blind, placebo-controlled clinical trial was conducted on 60 “intention to treat” subjects to evaluate the safety and efficacy of probiotic preparation Lactic Acid Bacillus (LAB containing active ingredient Bacillus coagulans strain LBSC) for the treatment of acute diarrhea with abdominal discomfort.

Methods

The Test-A arm (n = 30) was on B. coagulans LBSC [2 billion/g] and Placebo-B arm (n = 30) was on the carrier. The primary outcomes were the time to last unformed stool (TTLUS), number of unformed stools, change in severity of abdominal pain, time to complete resolution of abdominal discomfort, complete remission of diarrhea, and quality of life (QoL). The secondary outcomes were physical examination and vitals, hematological analysis, and assessment of reported adverse events (AEs) or serious adverse events (SAEs).

Results

Trial data showed that the LAB was well-tolerated by participants at the dose provided. The LAB was effective in recovering from acute diarrhea with abdominal pain and discomforts and exhibited improved cluster of QoL. No AEs or SAEs were reported during the trial.

Conclusions

It is evident that the test drug, i.e., LAB (B. coagulans strain LBSC) is safe and effective for improving the pathophysiological conditions related to acute diarrhea and abdominal discomfort evaluated through stage-II clinical trial.

Keywords

Bacillus coagulans Diarrhea Abdominal pain Bristol stool scale Quality of life 

Notes

Acknowledgements

Authors are grateful to Mr. V.L. Rathi, Mr. C.L. Rathi, Mr. Mukund Kabra, and Mr. Piyush Rathi at Advanced Enzyme Technologies Ltd. for their technical inputs and providing the laboratory facilities to carry out the study.

Author contribution statement

CM designed the study protocol, and monitored and prepared the manuscript. AKG reviewed the protocol and manuscript, and approved with technical inputs.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study is conducted in compliance with the applicable ethical standards Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), the relevant sections of Good Laboratory Practice (GLP), local laws and regulations, and the provisions of the Declaration of Helsinki. The EC Approval [Reference No.: RH/IEC/AP-002/2018 and Dated: 16/01/2018] and registration of the Clinical Trials Registry—India (CTRI) [Reference No.: CTRI/2018/01/011635 and Dated: 31/01/2018] were obtained prior to the clinical trial study.

Supplementary material

228_2018_2562_MOESM1_ESM.docx (25 kb)
ESM 1 (DOCX 24 kb)

References

  1. 1.
    World Health Organization (2018) The factsheet: antimicrobial resistance. http://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
  2. 2.
    World Health Organization (WHO) (2006) The treatment of diarrhea. A Manual for Physicians and Senior Health Workers WHO/ FCH/CAH/ 03.7Google Scholar
  3. 3.
    Gibson MK, Pesesky W, Dantas G (2014) The yin and yang of bacterial resilience in the human gut microbiota. J Mol Biol 426:3866–3876CrossRefGoogle Scholar
  4. 4.
    McFarland LV (2009) Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 15:274–280CrossRefGoogle Scholar
  5. 5.
    Johnston BC, Supina AL, Ospina M, Vohra S (2007) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev (2):CD004827.  https://doi.org/10.1002/14651858.CD004827.pub2
  6. 6.
    Konuray G, Erginkaya Z (2018) Potential use of Bacillus coagulans in the food industry. Foods 7:92.  https://doi.org/10.3390/foods7060092 CrossRefGoogle Scholar
  7. 7.
    La Rosa M, Bottaro G, Gulino N, Gambuzza F, Di Forti F, Inì G, Tornambè E (2003) Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study. Minerva Pediatr 55:447–452Google Scholar
  8. 8.
    Hun L (2009) Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 121:119–124CrossRefGoogle Scholar
  9. 9.
    Saneian H, Pourmoghaddas Z, Roohafza H, Gholamrezaei A (2015) Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 8:56–65Google Scholar
  10. 10.
    World Medical Association Declaration of Helsinki (2000) Ethical principles for medical research involving human subjects. 52nd WMA general assembly. Scotland, EdinburghGoogle Scholar
  11. 11.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice [E6(R1)], June 1996Google Scholar
  12. 12.
    Indian Council of Medical Research (ICMR) (2006) Ethical guidelines for biomedical research on human participants. New Delhi. http://www.cns.iisc.ac.in/wordpress/wpcontent/uploads/2017/01/ethical_guidelines.pdf. Accessed 2 Mar 2018
  13. 13.
    Amarenco G (2014) Bristol stool chart: prospective and monocentric study of “stools introspection” in healthy subjects. Prog Urol 24:708–713CrossRefGoogle Scholar
  14. 14.
    Food and Agriculture Organization (FAO) and World Health Organization (WHO) Expert Consultation (2001) Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization, CórdobaGoogle Scholar
  15. 15.
    European Food Safety Authority (2018) Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 7: suitability of taxonomic units notified to EFSA until September 2017. EFSA panel on biological hazards (BIOHAZ). EFSA J 16:e05131Google Scholar
  16. 16.
    Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Pande A, Majeed S, Ali F (2016) A double-blind, placebo-controlled, parallel study evaluating the safety of Bacillus coagulans MTCC 5856 in healthy individuals. J Clin Toxicol 6:1–9CrossRefGoogle Scholar
  17. 17.
    Sudha MR, Radkar N, Maurya A (2011) Effect of supplementation of probiotic Bacillus coagulans Unique IS-2 on hypercholesterolemia subjects: a clinical study. Int J Probiotics Prebiotics 6:89–94Google Scholar
  18. 18.
    Ara K, Meguro S, Hase T, Tokimitsu I, Otsuji K, Kawai S, Ito S, Iino H (2002) Effect of spore-bearing lactic acid-forming bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats. Microb Ecol Health Dis 14:4–13CrossRefGoogle Scholar
  19. 19.
    Dutta F, Mitra U, Dutta S, Rajendran K, Saha TK, Chatterjee MK (2011) Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as probiotic in clinical practice, on acute watery diarrhoea in children. Tropical Med Int Health 16:555–561CrossRefGoogle Scholar
  20. 20.
    Sudha RM, Bhonagiri S (2012) Efficacy of Bacillus coagulans strain Unique IS-2 in the treatment of patients with acute diarrhea. Int J Probiotics Prebiotics 7:33–37Google Scholar
  21. 21.
    Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK (2016) Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 15:21CrossRefGoogle Scholar
  22. 22.
    Stefano G, Licia P, Mona Abu Z, Jorge Amil D, Luigi Gobio C, Hans H, Sanja K, Karin M, Dusanka MT, Alexandra P, Jaime Salazar S, Bhupinder S, Hanna S, Zvi W (2000) Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 30:54–60CrossRefGoogle Scholar
  23. 23.
    Hania S, Jacek ZM (2001) Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 33:S17–S25CrossRefGoogle Scholar
  24. 24.
    Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ (2002) Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Digest Dis Sci 47:2625–2634CrossRefGoogle Scholar
  25. 25.
    Basu S, Paul DK, Ganguly S, Chatterjee M, Chandra PK (2009) Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol 43:208–213CrossRefGoogle Scholar
  26. 26.
    Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE (2006) Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 6:374–382CrossRefGoogle Scholar
  27. 27.
    Carabotti M, Scirocco A, Maselli MA, Severia C (2015) The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 28:203–209Google Scholar
  28. 28.
    Distrutti E, Cipriani S, Mencarelli A, Renga B, Fiorucci S (2013) Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One 8:e63893CrossRefGoogle Scholar
  29. 29.
    Theodorou V, Belgnaoui AA, Agostini S, Eutamene H (2014) Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes 5:430–436CrossRefGoogle Scholar
  30. 30.
    Ciorba MA (2012) A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol 10:960–968CrossRefGoogle Scholar
  31. 31.
    Kirjavainen PV, EINezami HS, Salminen SJ, Ahokas JT, Wright PFA (1999) Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp. shermanii JS on mouse lymphocyte proliferation. Clin Diagn Lab Immunol 6:799–802Google Scholar
  32. 32.
    Hungin APS, Mulligan C, Pot B, Whorwell P, Agreus L, Fracasso P, Lionis C, Mendive J, Foy JMP, Rubin G, Winchester C, Wit N (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence based international guide. Aliment Pharmacol Ther 38:864–886CrossRefGoogle Scholar
  33. 33.
    Roberts CM, Hoover DG (1996) Sensitivity of Bacillus coagulans spores to combinations of high hydrostatic pressure, heat, acidity and nisin. J Appl Microbiol 81:363–368CrossRefGoogle Scholar
  34. 34.
    Drago L, De Vecchi E (2009) Should Lactobacillus sporogenes and Bacillus coagulans have a future? J Chemother 21:371–377CrossRefGoogle Scholar
  35. 35.
    Casula G, Cutting SM (2002) Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol 68:2344–2352CrossRefGoogle Scholar
  36. 36.
    Dai C, Guandalini S, Zhao DH, Jiang M (2012) Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem 362:43–53CrossRefGoogle Scholar
  37. 37.
    Perez-Burgos A, Wang L, Neufeld KAM, Mao YK, Ahmadzai M, Janssen LJ, Stanisz AM, Bienenstock J, Kunze WA (2015) The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. J Physiol 593:3943–3957CrossRefGoogle Scholar
  38. 38.
    Rao RK, Samak G (2013) Protection and restitution of gut barrier by probiotics: nutritional and clinical implications. Curr Nutr Food Sci 9:99–107CrossRefGoogle Scholar
  39. 39.
    Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, Giovanni DD, Campanozzi A, Miele E, Staiano A (2017) A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome a multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol 51:e5–e10CrossRefGoogle Scholar
  40. 40.
    Suva MA, Sureja VP, Kheni DB (2016) Novel insight on probiotic Bacillus subtilis: mechanism of action and clinical applications. J Curr Res Sci Med 2:65–72CrossRefGoogle Scholar
  41. 41.
    Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR (2009) A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 9:85CrossRefGoogle Scholar
  42. 42.
    Lahiri K, Jadhav K, Gahlowt P, Najmuddin F (2015) Bacillus clausii as an adjuvant therapy in acute childhood diarrhea. IOSR J Dent Med Sci 14:74–76Google Scholar
  43. 43.
    Kim HJ, Camilleri M, Mckinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17:895–904CrossRefGoogle Scholar
  44. 44.
    Lawrence SJ, Korzenik JR, Mundy LM (2005) Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 54:905–906CrossRefGoogle Scholar
  45. 45.
    O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EMM (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterol 128:541–551CrossRefGoogle Scholar
  46. 46.
    Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101:1581–1590CrossRefGoogle Scholar
  47. 47.
    Giralt J, Regadera JP, Verges R, Romero J, Fuente I, Biete A, Villoria J, Cobo JM, Guarner F (2008) Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 71:1213–1219CrossRefGoogle Scholar
  48. 48.
    Lisa C, Gina B, Kathleen B, Autumn D, Beth M, Melanie O, Meghann S, Felicia V, Dawn W, Alison S, Jeffry K (2011) A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 45:785–789CrossRefGoogle Scholar
  49. 49.
    Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, Guyatt GH (2012) Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 157:878–888CrossRefGoogle Scholar
  50. 50.
    Rosa R, Floriana G, Mariabeatrice P, Annacinzia A, Rosa M, Alfredo DL, Enzo I (2013) Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol 8:169–172CrossRefGoogle Scholar
  51. 51.
    Minamida K, Nishimura M, Miwa K, Nishihira J (2015) Effects of dietary fiber with Bacillus coagulans lilac-01 on bowel movement and fecal properties of healthy volunteers with a tendency for constipation. Biosci Biotechnol Biochem 79:300–306CrossRefGoogle Scholar
  52. 52.
    Majeed M, Nagabhushanam K, Natarajan S, Vaidyanathan P, Arumugam S, Karri SK (2017) Process for the therapeutic management of darrhea predominant irritable bowel syndrome using Bacillus coagulans SBC-37-01, MTCC 5856. Patent No. US 9,579,352 B2. https://patentimages.storage.googleapis.com/2e/73/cd/f9a8344c81e152/US9579352.pdf. Accessed 15 Dec 2017
  53. 53.
    Drouault-Holowacza S, Bieuveleta S, Burckela A, Cazaubielb M, Drayc X, Marteauc P (2008) A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroentérol Clin Biol 32:147–152CrossRefGoogle Scholar
  54. 54.
    Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C (2009) A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutr 25:520–525CrossRefGoogle Scholar
  55. 55.
    Guglielmetti S, Mora D, Gschwender M, Popp K (2011) Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33:1123–1132CrossRefGoogle Scholar
  56. 56.
    Lee JY, Chu SH, Jeon JY, Lee MK, Park JH, Lee DC, Lee JW, Kim NK (2014) Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial. Dig Liver Dis 46:1126–1132CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Probiotics LaboratoryAdvanced Enzyme Technologies Ltd.Thane (W)India

Personalised recommendations